Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.51 |
| ▸ | NOS2 | P35228 | 7/20 | 0.43 |
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS3 | P29474 | 4/20 | 0.43 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566572 | 1.00 | BHMT (0.51) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL17234326 | 1.00 | BHMT (0.51) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL17234404 | 0.85 | BHMT (0.40) | BHMTNOS2NOS1NOS3CYP2C19 | |
| SCHEMBL18528398 | 0.85 | BHMT (0.40) | BHMTNOS2NOS1NOS3CYP2C19 | |
| SCHEMBL24241853 | 0.85 | BHMT (0.40) | BHMTNOS2NOS1NOS3CYP2C19 | |
| SCHEMBL21461373 | 0.82 | BHMT (0.48) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL17234324 | 0.82 | BHMT (0.48) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL23586839 | 0.82 | BHMT (0.48) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL21461374 | 0.82 | BHMT (0.48) | BHMTNOS2NOS1NOS3BHMT2 | |
| SCHEMBL18528335 | 0.80 | MVD (0.31) | BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | BHMT 505/4885NOS2 3755/4885NOS1 3768/4885 |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BHMT 902/4885NOS2 3782/4885NOS1 3763/4885 |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BHMT 902/4885NOS2 3782/4885NOS1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.